Last $56.69 USD
Change Today +1.73 / 3.15%
Volume 1.6M
PTCT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

ptc therapeutics inc (PTCT) Snapshot

Open
$57.03
Previous Close
$54.96
Day High
$57.50
Day Low
$54.88
52 Week High
12/19/14 - $57.50
52 Week Low
05/21/14 - $14.51
Market Cap
1.9B
Average Volume 10 Days
662.0K
EPS TTM
$-3.12
Shares Outstanding
33.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PTC THERAPEUTICS INC (PTCT)

Related News

No related news articles were found.

ptc therapeutics inc (PTCT) Details

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. Its lead product candidate is ataluren for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutations or nmCF. The company had completed a Phase IIb clinical trial of ataluren for the treatment of nmDMD and a Phase III clinical trial of ataluren for the treatment of nmCF. In addition, it develops spinal muscular atrophy, which is in Phase I clinical program. The company’s preclinical development programs include PTC596, a development candidate used for the treatment of chemotherapy resistant cancers; and antibacterial small molecule compounds for the treatment of life-threatening infections caused by multidrug-resistant Gram-negative bacteria. PTC Therapeutics, Inc. has collaborations with Roche and the SMA Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and AstraZeneca AB for the discovery and development of potential new therapies for cancer and other diseases. The company was founded in 1998 and is based in South Plainfield, New Jersey.

133 Employees
Last Reported Date: 03/6/14
Founded in 1998

ptc therapeutics inc (PTCT) Top Compensated Officers

Co-Founder, Chief Executive Officer and Execu...
Total Annual Compensation: $460.8K
Chief Commercial Officer
Total Annual Compensation: $368.2K
Compensation as of Fiscal Year 2013.

ptc therapeutics inc (PTCT) Key Developments

Food and Drug Administration and European Medicines Agency Grants Orphan Drug Designation to PTC Therapeutics's Translarna in the U.S. and Europe for the Treatment of Mucopolysaccharidosis I

PTC Therapeutics, Inc. announced that both the U.S. Food and Drug Administration and the European Medicines Agency have granted orphan-drug designation (ODD) to Translarna (ataluren) for the treatment of patients with Mucopolysaccharidosis I (MPS I). MPS I is an inherited genetic disorder caused by a deficiency in an essential enzyme that is responsible for the breakdown of by-products in the body's cells. There is significant unmet medical need and new treatments targeting the underlying cause of the disease are needed. MPS I represents the third indication for which Translarna has received orphan-drug designation. Translarna also has orphan-drug designation for Duchenne muscular dystrophy and cystic fibrosis. Translarna is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. In preclinical models of MPS I, Translarna demonstrated that it crosses the blood-brain barrier and penetrates skeletal and cardiac tissues. The same preclinical models indicate that Translarna treatment reduces GAG levels in multiple tissues with no observed signs of cell toxicity or stress. Since Translarna is administered systemically, crosses the blood-brain barrier, and penetrates other tissues relevant to disease, there is potential for Translarna treatment to address the cardiac and neurological defects associated with nonsense mutation MPS I. In the U.S., Orphan drug designation is granted by the FDA'sOffice of Orphan Products Development to promote the development of products that may offer therapeutic benefits for diseases with a prevalence of fewer than 200,000 individuals per year. Orphan-drug designation provides opportunities for grant funding towards clinical trial costs, tax advantages, FDA user-fee benefits, and seven years of market exclusivity in the United States, if granted FDA approval. Similarly, EMA's Orphan Medicinal Product Designation is designed to promote the development of drugs that may provide significant benefit to patients suffering from rare, life-threatening diseases. In addition to 10 years of market exclusivity if Translarna is approved for the treatment of nonsense mutation MPS I, the designation also provides special incentives for sponsors including eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees during development or at the time of application for marketing approval.

PTC Therapeutics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 09:10 AM

PTC Therapeutics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 09:10 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States.

PTC Therapeutics Announces Launch of Translarna (ataluren) in Germany

PTC Therapeutics, Inc. announced that Translarna(TM) (ataluren) is now commercially available to patients in Germany, the first country to launch in the European Union (EU), with first shipments expected to begin this week. The launch follows the European Commission marketing authorization, which was received in August 2014 for the use of Translarna to treat ambulatory patients with nonsense mutation Duchenne muscular dystrophy who are 5 years and older. A confirmatory Phase 3 clinical trial of Translarna, ACT DMD, in nonsense mutation Duchenne muscular dystrophy patients completed enrollment in September 2014. Top-line data is expected in the fourth quarter of 2015. Currently, Translarna is not approved for use in the United States. Translarna, discovered and developed by PTC Therapeutics, Inc., is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as dystrophin in Duchenne muscular dystrophy. Translarna is licensed in the European Economic Area for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older. Translarna is an investigational new drug in the United States. The development of Translarna has been supported by grants from Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation); Muscular Dystrophy Association; FDA's Office of Orphan Products Development; National Center for Research Resources; National Heart, Lung, and Blood Institute; and Parent Project Muscular Dystrophy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTCT:US $56.69 USD +1.73

PTCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTCT.
View Industry Companies
 

Industry Analysis

PTCT

Industry Average

Valuation PTCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 97.9x
Price/Book 8.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 99.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PTC THERAPEUTICS INC, please visit www.ptcbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.